Test bank for Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, 8th Edition by Nader Rifai, PhD Chapters 1 - 49  

Test bank for Tietz Fundamentals of Clinical Chemistry
and Molecular Diagnostics,
8th Edition by Nader Rifai, PhD
Chapters 1 - 49

,TietzlvFundamentalslvoflvClinicallvChemistrylvandlvMolecularlvDiagnosticslv8thl v EditionlvTestlvBank
Tablelvoflvcontents:
I.lvPrincipleslvOflvLaboratorylvMedicine
Chapterlv1.lvClinicallvChemistry,lvMolecularlvDiagnostics,lvandlvLaboratorylvMedicine
Chapterlv2.lvSelectionlvandlvAnalyticallvEvaluationlvoflvMethodslv—lvWithlvStatisticallvTechniques
Chapterlv3.lvClinicallvEvaluationlvoflvMethods
Chapterlv4.lvEvidence-BasedlvLaboratorylvMedicine
Chapterlv5.lvEstablishmentlvandlvUselvoflvReferencelvValues
Chapterlv6.lvSpecimenlvCollection,lvProcessing,lvandlvOtherlvPreanalyticallvVariables
Chapterlv7.lvQualitylvManagement
II.lvAnalyticallvTechniqueslvAndlvInstrumentation
Chapterlv8.lvPrincipleslvoflvBasiclvTechniqueslvandlvLaboratorylvSafety
Chapterlv9.lvOpticallvTechniques
Chapterlv10.lvElectrochemistrylvandlvChemicallvSensors
Chapterlv11.lvElectrophoresis
Chapterlv12.lvChromatography
Chapterlv13.lvMasslvSpectrometry
Chapterlv14.lvEnzymelvandlvRatelvAnalyses
Chapterlv15.lvImmunochemicallvTechniques
Chapterlv16lvAutomation
Chapterlv17.lvPoint-of-CarelvInstrumentation
III.l v Analytes
Chapterlv18.lvAminolvAcids,lvPeptides,lvandlvProteins
Chapterlv19.lvSerumlvEnzymes
Chapterlv20.lvTumorlvMarkerslvandlvCancerlvGenes
Chapterlv21.lvKidneylvFunctionlvTestslv—lvCreatinine,lvGFR,lvUrea,lvandlvUriclvAcid
Chapterlv22.lvCarbohydrates
Chapterlv23.lvLipids,lvLipoproteins,lvApolipoproteins,lvandlvOtherlvCardiaclvRisklvFactors
Chapterlv24.lvElectrolyteslvandlvBloodlvGases
Chapterlv25.lvHormones
Chapterlv26.l v CatecholamineslvandlvSerotonin
Chapterlv27.l v Vitamins,lvTracelvElements,lvNutritionallvAssessment
Chapterlv28.lvHemoglobin,lvIron,lvandlvBilirubin
Chapterlv29.lvPorphyrinslvandlvPorphyrias
Chapterlv30.lvTherapeuticlvDrugslvandlvTheirlvManagement
Chapterlv31.lvClinicallvToxicology
Chapterlv32.l v ToxiclvMetals
IV.l v Pathophysiology
Chapterlv33.lvDiabetes

,Chapterlv34.l v CardiovascularlvDisease
Chapterlv35.lvKidneylvDisease
Chapterlv36.l v PhysiologylvandlvDisorderslvoflvWater,lvElectrolyte,lvandlvAcid-BaselvMetabolism
Chapterlv37.lvlvLiverlvDisease
Chapterlv38.l v GastrointestinallvandlvPancreaticlvDiseases
Chapterlv39.lvlvDisorderslvoflvBonelvandlvMinerallvMetabolism
Chapterlv40.lvlvDisorderslvoflvthelvPituitarylvGland
Chapterlv41.l v DisorderslvoflvthelvAdrenallvCortex
Chapterlv42.l v ThyroidlvDisorders
Chapterlv43.l v Reproduction-RelatedlvDisorders
Chapterlv44.lvlvPregnancylvandlvPrenatallvTesting
Chapterlv45.l v NewbornlvScreeninglvandlvInbornlvErrorslvoflvMetabolism
Chapterlv46.lvPharmacogenetics
V.l v MolecularlvDiagnostics
Chapterlv47.lvPrincipleslvoflvMolecularlvBiology
Chapterlv48.lvNucleiclvAcidlvTechniqueslvandlvApplications
Chapterlv49.lvGenomeslvandlvNucleiclvAcidlvAlterations

, Chapterlv01:lvClinicallvChemistry,lvMolecularlvDiagnostics,lvandlvLaboratorylvMedicinelv
TestvlBank

MULTIPLElvCHOICE

1. Anlvindividuallvworkinglvinlvalvclinicallvchemistrylvlaboratorylvislvmarriedlvtolvalvsaleslvrepresenta
tivelvwholvworkslvforlvalvcompanylvthatlvsellslvchemistrylvlaboratorylvsupplies.lvWhenlvthelvlabora
torylvmanagerlvrequestslvalvlistlvoflvneededlvsupplies,lvcostlvoflvsupplies,lvandlvvendors,lvthislvindivi
duallvonlylvrecommendslvthelvspouse’slvcompanylvaslvthelvvendor.lvThislvislvconsideredlvtolvbelva(n)
:
a. accountinglvissue.
b. possiblelvconflictlvoflvinterest.
c. maintenancelvoflvconfidentialitylvissue.
d. problemlvwithlvresourcelvallocation.

ANS:l v B
Concernlvhaslvbeenlvraisedlvoverlvthelvinterrelationshipslvbetweenlvpractitionerslvinlvthelvmedicallvf
ieldvlandlvcommerciallvsupplierslvoflvdrugs,lvdevices,lvequipment,lvetc.,lvtolvthelvmedicallvprofessio
n.
Similarly,lvrelationshipslvhavelvbeenlvscrutinizedlvbetweenlvclinicallvlaboratorianslvandlvmanufact
urerslvandlvproviderslvoflvdiagnosticlvequipmentlvandlvsupplies.lvTheselvconcernslvledlvthelvNationa
llvInstituteslvoflvHealthlv(NIH)lvinlv1995lvtolvrequirelvofficiallvinstitutionallvreviewlvoflvfinanciallvdis
closurelvbylvresearcherslvandlvmanagementlvoflvsituationslvinlvwhichlvdisclosurelvindicateslvpotentia
lvlconflictslvoflvinterest.

DIF: 1 REF:lvlvlvPagelv4-5 OBJ:l v 6lv|lv7

2. Alvpatientlvvisitslvherlvphysicianlvstatinglvthatlvherlvprescribedlvpainkillerlvislvnotlvworkinglvtolvre
ducelvthelvpainlvfollowinglvherlvrecentlvsurgery.lvAlvfriendlvoflvthelvpatientlvclaimslvthatlvthelvsam
elvpainkillerlv“workedlvwonders”lvtolvreducelvherlvpainlvafterlvthelvsamelvsurgery.lvThelvphysicianl
vstateslvthatlvthelvdifferencelvinlvthelveffectlvoflvthelvdruglvmightlvbelvcausedlvby

,lvwhichlvislvstudiedlvinlvpharmacogenetics.
a. epidemiology
b. anlvinheritedlvdisease
c. alvconflictlvoflvinterest
d. alvgeneticlvvariationlvinlvdrug-metabolizinglvenzymes
ANS:l v D
Pharmacogeneticslvislvthelvstudylvoflvthelvgeneticlvvariationlvoflvdruglvmetabolismlvbetw
eenlvindividuals.

DIF: 1 REF:lvlvlvPagelv3 OBJ:l v 1

3. Johnlvworkslvinlvalvmolecularlvdiagnosticslvlaboratorylvandlvreceiveslvalvbloodlvsamplelvthatlvhasl
vthelvnamelvoflvalvcloselvfriendlvprintedlvonlvthelvbar-
codedlvlabel.lvThelvgeneticlvtestlvthatlvislvorderedlvonlvthelvfriend’slvsamplelvwouldlvprovidelvdiagn
osticlvinformationlvaboutlvalvdisorderlvthatlvhaslvalvpoorlvprognosis,lvandlvthelvtestlvislvusuallylvper
formedlvbylvJohn.lvHelvaskslvalvfellowlvemployeelvtolvanalyzelvthelvsamplelvforlvhimlvandlvnotlvdiv
ulgelvthelvresults.lvThislvethicallvissuelvconcerns:
a. confidentialitylvoflvpatientlvgeneticlvandlvmedicallvinformation.
b. alvconflictlvoflvinterest.
c. resourcelvallocation.
d. diagnosticlvaccuracy.